Genmab A/S (GMAB)
Develops antibody drugs to treat cancer, blood disorders, and immune diseases
$29.00+0.01%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago+33.1%
The outlook
Genmab trades at $29 with strong analyst backing—the consensus leans heavily Buy, and the average price target sits roughly 31% above current levels. The stock sits midway in its 52-week range with mixed momentum against moving averages. At a trailing P/E of 22.1, the overall data leans bullish, though price action remains subdued.
What’s behind the score
Analyst consensusStrong Buy — 1.2 avg of 10 analysts
Price trendMixed vs its moving averages
52-week range55% of the way from its 52-week low to high
Price targetAvg target +31% vs current price
Analyst price target
~12-month · 10 analysts$37.96average target+30.9% vs now
Now $29.00
Low $32.00High $43.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$17.80B
52-wk high
$35.43
52-wk low
$21.00
50-day avg
$26.85
200-day avg
$29.13
Trailing P/E
22.1